Clarity Pharmaceuticals Limited (ASX: CU6), a clinical stage radiopharmaceutical company focused on advancing cancer treatment outcomes, has entered into a significant agreement with PETNET Solutions Inc, a leading manufacturer of radiopharmaceuticals for PET imaging in the US. The Master Service Agreement and Clinical Supply Agreement will facilitate the production of Clarity's 64Cu SAR-bisPSMA, a next-generation diagnostic radiopharmaceutical for prostate cancer imaging.
PETNET Solutions will manufacture the ready-to-use 64Cu SAR-bisPSMA in compliance with current Good Manufacturing Practice (cGMP) guidelines for Clarity's US-based clinical trials. This investigational PET agent is expected to commence a pivotal Phase III trial in the US by the end of FY2023 and potentially a second Phase III trial in FY2024. The collaboration between the companies also paves the way for streamlined technology transfer of other Cu-64 based imaging agents from Clarity to PETNET Solutions for current and future clinical trials in the US.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
